- Home
- / Ginwa Enterprise
Ginwa Enterprise
Stock Price
¥6.6
2024-10-29
Market Capitalization
¥2.4 B
2024-10-29
Revenue
¥579 M
FY, 2024
Ginwa Enterprise Summary
Company Summary
- Overview
- Ginwa Enterprise (银花企业集团) is a pharmaceutical company that produces biological and chemical medicines. It offers norfloxacin capsules, tannic acid protein yeast powders, hydrochloride tablets, compound mixtures, and other products.
- Type
- Public
- Status
- Active
- Founded
- 1997
- HQ
- Xian, CN | view all locations
- Website
- http://www.ginwa.com.cn
- Cybersecurity rating
Table of Contents
LocationsView all
1 location detected
Xian HQ
China
No.202, Keji 4th Road, High-Tech Industrial Development Zone
Ginwa Enterprise Financials
Summary Financials
- Revenue (Q3, 2025)
- ¥141.6M
- Gross profit (Q3, 2025)
- ¥107.3M
- Net income (Q3, 2025)
- ¥28.1M
- Cash (Q3, 2025)
- ¥235.5M
- EBIT (Q3, 2025)
- ¥12.0M
- Enterprise value
- $2.3B
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026